Edgar Filing: SCHALLER CHARLES R - Form 4

SCHALLER CH Form 4										
September 03, 20								OMB A	PPROVAL	
	UNITED	STATES	N OMB Number:	3235-0287						
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							Estimated burden hou response	Estimated average burden hours per response 0.5	
1(b).										
(Print or Type Respo	nses)									
1. Name and Address of Reporting Person <u>*</u> SCHALLER CHARLES R			2. Issuer Name and Ticker or Trading Symbol MEDAREX INC [MEDX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) 8 BONNIE SHC LANDING, 407	3. Date of Earliest Transaction (Month/Day/Year) 09/01/2009				X_ Director 10% Owner Officer (give title Other (specify below) below)					
	4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
OKATIE, SC 29		(7:)					Person			
	(State)	(Zip)					Acquired, Disposed		-	
	ansaction Date hth/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report or	n a separate line	for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
					inforr requi	nation con red to resp ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	
Derivative	Conversion	(Month/Day/Year)	Day/Year) Execution Date, if		iorDerivative	Expiration Date	Underlying Securities	
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	

Edgar Filing: SCHALLER CHARLES R - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				
				Code V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 14.92	09/01/2009		D	18,000	<u>(1)</u>	05/16/2017	Common Stock	18,000
Stock Option (Right to Buy)	\$ 9.84	09/01/2009		D	18,000	(2)	07/25/2015	Common Stock	18,000
Stock Option (Right to Buy)	\$ 7.91	09/01/2009		D	18,000	<u>(3)</u>	05/14/2018	Common Stock	18,000
Stock Option (Right to Buy)	\$ 7.48	09/01/2009		D	14,000	<u>(4)</u>	07/22/2012	Common Stock	14,000
Stock Option (Right to Buy)	\$ 5.59	09/01/2009		D	14,000	(5)	07/23/2013	Common Stock	14,000
Stock Option (Right to Buy)	\$ 4.89	09/01/2009		D	18,000	<u>(6)</u>	08/10/2014	Common Stock	18,000
Stock Option (Right to Buy)	\$ 3.72	09/01/2009		D	18,000	(7)	03/04/2019	Common Stock	18,000
Restricted Stock Units	<u>(8)</u>	09/01/2009		D	3,161	<u>(9)</u>	(11)	Common Stock	3,161
Restricted Stock	<u>(8)</u>	09/01/2009		D	6,721	(10)	(11)	Common Stock	6,721

Reporting Owners

Reporting Owner Name / Address

Relationships

Edgar Filing: SCHALLER CHARLES R - Form 4

Director 10% Owner Officer Other

SCHALLER CHARLES R 8 BONNIE SHORE LANDING 4072 SPRING ISLAND OKATIE, SC 29909

Signatures

Beth Behrend, Attorney-in-Fact 09/0

09/03/2009

**Signature of Reporting Person

Date

X

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option was canceled in the merger in exchange for a cash payment of \$19,530.00, respresenting the difference between the exercise
 price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$110,970.00, respresenting the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$145,620.00, respresenting the difference between the

(3) exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$119,287.00, respresenting the difference between the
 (4) exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$145,740.00, respresenting the difference between the
 (5) exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$200,070.00, respresenting the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

This option was canceled in the merger in exchange for a cash payment of \$221,040.00, respresenting the difference between the
 exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.

- (8) Each restricted stock unit respresents a contingent right to receive one (1) share of Medarex, Inc. common stock.
- (9) This restricted stock unit was canceled in the merger in exchange for a cash payment of \$50,576.00, based on the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (10) This restricted stock unit was canceled in the merger in exchange for a cash payment of \$107,536.00, based on the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (11) The restricted stock units vested ratably on each of the first, second and third anniversaries of the grant date and the receipt of the shares of common stock was deferred until the individual's retirement or separation of service from the Board.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.